These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27618777)

  • 1. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.
    Miao R; Wu Y; Zhang H; Zhou H; Sun X; Csizmadia E; He L; Zhao Y; Jiang C; Miksad RA; Ghaziani T; Robson SC; Zhao H
    Sci Rep; 2016 Sep; 6():33121. PubMed ID: 27618777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.
    Liu X; Liao W; Yuan Q; Ou Y; Huang J
    Oncotarget; 2015 Oct; 6(33):34309-20. PubMed ID: 26418879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21.
    Zhang H; Yao W; Zhang M; Lu Y; Tang J; Jiang M; Mou X; You G; Liang X
    Biochem Biophys Res Commun; 2021 Apr; 550():84-91. PubMed ID: 33689884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
    Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
    PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TTK Inhibitors as a Targeted Therapy for
    Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
    Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of
    Tsai YM; Wu KL; Chang YY; Hung JY; Chang WA; Chang CY; Jian SF; Tsai PH; Huang YC; Chong IW; Hsu YL
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
    Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
    Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
    PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
    Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
    Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression.
    Kronschnabl P; Grünweller A; Hartmann RK; Aigner A; Weirauch U
    Int J Oncol; 2020 Feb; 56(2):448-459. PubMed ID: 31894300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
    Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
    Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.
    Miao Y; Konno Y; Wang B; Zhu L; Zhai T; Ihira K; Kobayashi N; Watari H; Jin X; Yue J; Dong P; Fang M
    J Transl Med; 2023 Feb; 21(1):151. PubMed ID: 36829176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
    Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
    Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.
    Stratford JK; Yan F; Hill RA; Major MB; Graves LM; Der CJ; Yeh JJ
    PLoS One; 2017; 12(4):e0174863. PubMed ID: 28380042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.
    Chandler BC; Moubadder L; Ritter CL; Liu M; Cameron M; Wilder-Romans K; Zhang A; Pesch AM; Michmerhuizen AR; Hirsh N; Androsiglio M; Ward T; Olsen E; Niknafs YS; Merajver S; Thomas DG; Brown PH; Lawrence TS; Nyati S; Pierce LJ; Chinnaiyan A; Speers C
    J Clin Invest; 2020 Feb; 130(2):958-973. PubMed ID: 31961339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
    Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
    Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis underlying resistance to Mps1/TTK inhibitors.
    Koch A; Maia A; Janssen A; Medema RH
    Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer.
    Chen X; Yu C; Gao J; Zhu H; Cui B; Zhang T; Zhou Y; Liu Q; He H; Xiao R; Huang R; Xie H; Gao D; Zhou H
    Theranostics; 2018; 8(9):2348-2360. PubMed ID: 29721084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G
    Zhu D; Xu S; Deyanat-Yazdi G; Peng SX; Barnes LA; Narla RK; Tran T; Mikolon D; Ning Y; Shi T; Jiang N; Raymon HK; Riggs JR; Boylan JF
    Mol Cancer Ther; 2018 Aug; 17(8):1727-1738. PubMed ID: 29866747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.